EMA Authorised: Taxotere (docetaxel) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA authorised Taxotere (docetaxel) for multiple cancer indications including head and neck cancer, non-small cell lung cancer, gastric cancer, prostate can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Breast Cancer
• Gastric Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Status: Authorised. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms. MAH: Sanofi Winthrop Industrie. Decision date: 30/07/2024